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Human papillomavirus (HPV) type-speciﬁc distribution was evaluated in genital samples collected from 654 women from the
South of Italy undergoing voluntary screening and correlated with cyto-histological abnormalities. HPV DNA was detected in
45.9% of the samples, 41.7% of which had multiple infection and 89.0% had high-risk HPV infection. The prevalence of HPV
infection and the rate of multiple infections decreased with age, suggesting natural selection of HPV types with better ﬁtness. In
line with other Italian studies, the most common HPV types were HPV-6 and HPV-16, followed by HPV-51, HPV-31, HPV-53,
and HPV-66, in women with both normal and abnormal cytology. Cervical intraepithelial lesions grade 2 or3 were associated with
high-risk HPV-16, HPV-18, HPV-31, and HPV-51 infection. These data indicate that prophylactic HPV vaccination is expected
to reduce the burden of HPV-related cervical lesions in this population, but also suggest the potential utility of new vaccines with
larger type coverage.
Copyright © 2009 Paola Menegazzi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
With the advent of the HPV vaccine, data on genotype-
speciﬁc prevalence of HPV infection in sexually active female
population would be useful to predict the potential beneﬁts
ofHPVvaccinationandtomonitortheimpactofvaccination
on HPV type replacement. A recent meta-analysis estimated
that the worldwide HPV prevalence in the cervix of women
withnormalcytologyisabout10.4%[1].HPV-16isthemost
common HPV type both in women with normal cervical
cytologyandinthosewithcervicallesionsorcancer,followed
by HPV-18 in Europe, Central and South America, HPV-52
and HPV-58 in Asia, and HPV-53 and HPV-52 in Northern
America [1, 2]. The pattern of HPV type distribution may
vary even among countries and regions, being related to
sexual habits and migrations of people, as suggested by
detection of HPV types typically found in Asia and Africa
and also in southern Europe [2, 3].
This cross-sectional study describes HPV prevalence and
type distribution in cervical samples from women resident
in southern areas of Italy, that is, Apulia region and Naples
area, who were referred for opportunistic screening and for
gynaecological care for evaluation of suspected HPV-related
lesions.
2.MaterialandMethods
2.1. Study Population and Specimens Collection. From 2005
to 2008, a total of 654 genital swabs, which were collected
from women aged from 17 to 60 years and living in
Apulia region (provinces of Lecce, Brindisi, Taranto and
Bari) and Naples city in the South of Italy, were analyzed.
Women were referred to laboratory “Dr. Pignatelli (Lecce-
Italy, departments of Virology & Molecular biology and
Cyto-hystopatology) for opportunistic screening and for
evaluation of HPV-associated lesions, so this patient popu-
lation does not represent the general population of women
attending public screening programs. The in force Italian
privacy law did not allow to collect any data about life-style,
sexual partners’ number, and so forth. Most samples (87%)
were cervical swabs, 3.5% were vulvar swabs, 3% vaginal,
and 6.5% other genital swabs. Samples were stored in 1.5mL
saline solution at −20◦C until DNA puriﬁcation.2 Infectious Diseases in Obstetrics and Gynecology
2.2.PCRAmpliﬁcationofHPVDNA. Total DNA was puriﬁed
from150µLcellularsuspensionbyusinganABIPRISM6100
System (Applied Biosystems inc., Monza, Italy) and eluted in a
ﬁnal volume of 120µL; 10µL of each DNA sample were used
for HPV PCR analysis. HPV PCR was performed using the
SPF10 primers (INNOLiPA HPV genotyping, Innogenetics
srl–Pomezia, Italy), which amplify a 65-bp fragment of the
L1 open reading frame and allow detection of at least 28
diﬀerent HPV types by hybridization on oligonucleotide
probes [4, 5], as described in the commercial kit protocol.
Appropriate negative and positive controls were included in
each session to monitor cross-contamination and eﬃciency
of DNA puriﬁcation and PCR ampliﬁcation.
2.3. HPV Genotyping by Using the INNO-LiPA HPV Geno-
typing System. The INNO-LiPA HPV genotyping system can
identify the following HPV types: HPV-6, 11, 16, 18, 26, 31,
33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66,
68, 69/71, 70, 73, 74 and 82. HPV types 16, 18, 26, 31, 33, 35,
39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82 were deﬁned
high-risk (HR) HPV types, whereas the other types were
deﬁned low-risk (LR) HPVs [6]. Recently, HPV classiﬁcation
has been revised and HPV-26, 53, 66, 73, and 82 have been
downgraded from the category of probably carcinogenic
(Group 2A) to possibly carcinogenic (Group 2B) [7, 8]. HPV
genotyping assay was performed as previously described [9].
After drying, the strips were visually interpreted using the
reference guide provided, according to the manufacturer’s
protocol.
2.4. Statistical Analysis. The association between HPV infec-
tion and clinical variables was assessed through the Chi-
square test. A P value of less than .05 was considered
statistically signiﬁcant.
3. Results
HPV DNA was identiﬁed in 300 of 654 samples (45.9%);
175 (58.3%) samples had single infection and 125 (41.7%)
had multiple infection. Among HPV-positive samples, 267
(89.0%) had HR-HPV infection (Table 1). HPV-6 and HPV-
16 were the most commonly detected types, both in single
andmultipleinfections,followedbyHPV-51,HPV-31,HPV-
66, and HPV-53. HPV-16 was signiﬁcantly more frequent in
single infection, whereas other HR-HPV types (i.e., HPV-
56, HPV-58, and HPV-68) were more frequently identiﬁed
in multiple infection (Table 1).
HPV DNA detection rate decreased with age, placing on
56.1% for women under 40 and on 37.7% in older ones
(Chi-square trend test, P<. 0001), as well as the prevalence
of multiple HPV infections tended to decrease with age,
probably due to selection by immunity or HPV type ﬁtness,
as suggested by the diﬀerent distribution of HPV types in
diﬀerent age groups.
In the 231 women who performed both HPV typing and
PAPtest,HPVDNAwasfoundinabout50%ofnegativePAP
tests (n = 208) and ASC-US (n = 11) and in 83.3% of LSIL
Table 1: HPV type distribution (%) in single and multiple
infections.
HPV genotype Single infections Multiple infections
(n = 175) (n = 125)
HPV-6 15.4 11.8
HPV-11 0.6 0.7
HPV-16∗ 14.9 7.2
HPV-18 1.1 2.6
HPV-26 0.0 0.0
HPV-31 8.0 7.6
HPV-33 1.1 1.0
HPV-35 1.1 1.0
HPV-39 3.4 5.6
HPV-40 0.6 1.0
HPV-42 1.1 0.7
HPV-43 0.6 0.0
HPV-44 1.1 2.0
HPV-45 0.0 1.3
HPV-51 9.1 6.9
HPV-52 6.3 6.3
HPV-53 7.4 6.6
HPV-54 6.3 4.6
HPV-56∗ 0.6 4.6
HPV-58 5.7 5.6
HPV-59 3.4 1.3
HPV-66 7.4 8.2
HPV-68∗ 0.6 6.3
HPV-69/71 0.0 0.3
HPV-70 2.3 1.0
HPV-73∗ 0.0 2.3
HPV-74 1.7 3.3
HPV-82 0.0 0.3
∗P<. 05; single infection versus multiple infection.
(n = 12; no cases of HSIL were identiﬁed). Detection of HR-
HPVswascommon(80%)bothinnormalandabnormalPap
smears.
Histological analyses were performed in 86 women who
underwent colposcopy and cervical biopsy. HPV DNA was
detected in 56.1% of biopsies with negative histology, 60.9%
of which had HR-HPVs. The prevalence of HPV-DNA (and
HR-HPV DNA) detection progressively increases with the
worsening of histological pattern, with 100% CIN-2/3 cases
positive for HR-HPVs, including HPV-16, HPV-18, HPV-31,
and HPV-51 (Table 2).
4. Discussion
This study on a female population from the South of Italy
undergoing HPV testing for opportunistic screening or for
evaluation of genital lesions shows a relatively high preva-
lenceofHPVinfection,40%ofwhichinvolvedmultipleHPV
types. The most frequent HPV types were HPV-6, HPV-16,
HPV-51, HPV-31, HPV-53, and HPV-66, with a diﬀerentInfectious Diseases in Obstetrics and Gynecology 3
Table 2: HPV prevalence and type distribution in diﬀerent histological patterns.
Histological
diagnosis
HPV-DNA
positiveNo. (%)
HR-HPV
positiveNo. (%)
HPV types detected in age groups
17–30 yr 31–40 yr 41–50 yr 51–60 yr
Negative
(n = 41) 23 (56.1) 14 (60.9)
HPV-31, 51,
54, 59, 66, 68,
70
HPV-6, 16,
31/54, 39, 51,
52, 53, 54, 56,
58, 66, 74
HPV-6, 31,
39, 51, 52, 53
HPV-6, 18,
54
HPV lesion
(n = 27) 21 (77.8) 20 (95.2)
HPV-6, 16,
18/39, 31, 39,
40, 52, 56, 66,
68
HPV-6, 16, 18,
31, 35, 39, 42,
44, 51, 52, 53,
58, 68/73
HPV-31, 52,
53
C I N1( n = 9) 8 (88.9) 7 (87.5) HPV-6, 16 HPV-16, 35, 51,
66 HPV-16, 58
CIN 2-3 (n = 9) 9 (100.0) 9 (100.0) HPV-18,
31/54, 51, 56
HPV-6, 16,
31/54, 51, 53 HPV-16 HPV-16,
31, 51
distribution in young versus older women, suggesting the
existence of a natural selection of HPV types which preserve
a better ﬁtness, such as HPV-16 and HPV-31. HR-HPVs
weredetectedinallCIN-2/3samples,withHPV-16,HPV-18,
HPV-31, and HPV-51 as the most frequent types. However,
HR-HPV types were detected also in a high rate in women
with a negative Pap test or with a negative histology.
These ﬁndings are in agreement with other studies on
HPV infection and type distribution in Italian women from
diﬀerent regions and in other European countries. In fact,
a high prevalence of HPV infection, mostly caused by HR-
HPV types, has been observed also in other Italian regions
[10–18]. All studies concordantly demonstrate that HPV-
16 is by far the most common type, followed by HPV-66,
HPV-31,HPV-51,HPV-52,HPV-53,andHPV-58(therating
order varies among series), while HPV-18 and HPV-45 are
less common [11–18]. At variance with studies on women
participating in organized cervical screening programs [10],
HPV-6 was frequently detected in our patients, who were
often referred for suspected condylomas.
SimilarHPVtypedistributionhasbeenrecentlyreported
from other European countries, such as Denmark [19]a n d
Germany [20], where HPV-16 was shown to be the most
common HPV type, followed by HPV-31, HPV-51, HPV-52,
HPV-53, and HPV-66.
In the present study, HR-HPVs, including HPV-16,
HPV-18, HPV-31, and HPV-51, were detected in 100% of
CIN2/3 lesions. The same distribution of HR-HPV types
was identiﬁed in high-grade cervical lesions investigated in
other Italian regions [12, 18, 21] and European countries
[19, 20, 22].
5. Conclusion
The results of this paper provide information on HPV type
distributioninwomenfromSouthernItalyand,byarevision
of the recent literature, indicate that the epidemiology of
HPV infection in these areas is not diﬀerent from other
Italian regions and from other European countries. Besides
HPV-16 and HPV-18, which are targeted by the currently
available HPV vaccines, other HR-HPVs, such as HPV-
31 and HPV-51, appear to be diﬀused in the population
of sexually active women and to be associated with high-
grade cervical lesions. These HPVs should be taken into
consideration in the development of enhanced vaccines with
larger type coverage.
Acknowledgment
We are very grateful to dr. Valtere Orgiato for his precious
contribution in the English revision.
References
[1] S. de Sanjos´ e, M. Diaz, X. Castellsagu´ e, et al., “Worldwide
prevalence and genotype distribution of cervical human
papillomavirusDNAinwomenwithnormalcytology:ameta-
analysis,” Lancet Infectious Diseases, vol. 7, no. 7, pp. 453–459,
2007.
[ 2 ]F .X .B o s c h ,A .N .B u r c h e l l ,M .S c h i ﬀman, et al., “Epidemi-
ology and natural history of human papillomavirus infection
and type-speciﬁc implications in cervical neoplasia,” Vaccine,
vol. 26, supplement 10, pp. K1–K16, 2008.
[3] L. Barzon, C. Giorgi, F. M. Buonaguro, and G. Pal` u, “Guide-
lines of the Italian Society for Virology on HPV testing and
vaccination for cervical cancer prevention,” Infectious Agents
and Cancer, vol. 3, no. 1, article 14, 2008.
[4] B. Kleter, L.-J. van Doorn, J. Schegget, et al., “Novel short-
fragment PCR assay for highly sensitive broad-spectrum
detection of anogenital human papillomaviruses,” American
Journal of Pathology, vol. 153, no. 6, pp. 1731–1739, 1998.
[5] W. J. G. Melchers, J. M. J. E. Bakkers, J. Wang, et al., “Short
fragment polymerase chain reaction reverse hybridization line
probe assay to detect and genotype a broad spectrum of
human papillomavirus types: clinical evaluation and follow-
up,” American Journal of Pathology, vol. 155, no. 5, pp. 1473–
1478, 1999.
[6] N. Mu˜ noz, F. X. Bosch, S. de Sanjos´ e, et al., “Epidemiologic
classiﬁcation of human papillomavirus types associated with
cervical cancer,” The New England Journal of Medicine, vol.
348, no. 6, pp. 518–527, 2003.4 Infectious Diseases in Obstetrics and Gynecology
[7] P. E. Castle, “The evolving deﬁnition of carcinogenic human
papilloma virus,” Infectious Agents and Cancer, vol. 4, article 7,
2009.
[8] M. Schiﬀman, G. Cliﬀord, and F. M. Buonaguro, “Classiﬁ-
cation of weakly carcinogenic human papillomavirus types:
addressing the limits of epidemiology at the borderline,”
Infectious Agents and Cancer, vol. 4, article 8, 2009.
[9] B. Kleter, L.-J. van Doorn, L. Schrauwen, et al., “Development
and clinical evaluation of a highly sensitive PCR-reverse
hybridization line probe assay for detection and identiﬁcation
of anogenital human papillomavirus,” Journal of Clinical
Microbiology, vol. 37, no. 8, pp. 2508–2517, 1999.
[10] G. Ronco, V. Ghisetti, N. Segnan, et al., “Prevalence of human
papillomavirus infection in women in Turin, Italy,” European
Journal of Cancer, vol. 41, no. 2, pp. 297–305, 2005.
[11] M. A. De Francesco, F. Gargiulo, C. Schreiber, G. Ciravolo, F.
Salinaro, and N. Manca, “Detection and genotyping of human
papillomavirus in cervical samples from Italian patients,”
Journal of Medical Virology, vol. 75, no. 4, pp. 588–592, 2005.
[12] M. L. Tornesello, M. L. Duraturo, G. Botti, et al., “Prevalence
of alpha-papillomavirus genotypes in cervical squamous
intraepithelial lesions and invasive cervical carcinoma in the
Italianpopulation,”JournalofMedicalVirology,vol.78,no.12,
pp. 1663–1672, 2006.
[13] P. Ammatuna, L. Giovannelli, D. Matranga, S. Ciriminna,
and A. Perino, “Prevalence of genital human papilloma virus
infection and genotypes among young women in Sicily, South
Italy,” CancerEpidemiologyBiomarkersandPrevention,vol.17,
no. 8, pp. 2002–2006, 2008.
[14] R. Verteramo, A. Pierangeli, E. Calzolari, et al., “Direct
sequencing of HPV DNA detected in gynaecologic outpatients
in Rome, Italy,” Microbes and Infection, vol. 8, no. 9-10, pp.
2517–2521, 2006.
[15] F. Gargiulo, M. A. De Francesco, C. Schreiber, et al.,
“Prevalence and distribution of single and multiple HPV
infections in cytologically abnormal cervical samples from
Italian women,” Virus Research, vol. 125, no. 2, pp. 176–182,
2007.
[16] R. Del Prete, A. M. D. Taranto, M. R. Lipsi, V. Nirchio,
R. Antonetti, and G. Miragliotta, “Prevalence and genotypes
identiﬁcation of human papillomavirus infection in a popula-
tion of South Italy,” Journal of Clinical Virology, vol. 42, no. 2,
pp. 211–214, 2008.
[17] S. Menzo, A. Ciavattini, P. Bagnarelli, K. Marinelli, S. Sisti,
and M. Clementi, “Molecular epidemiology and pathogenic
potential of underdiagnosed human papillomavirus types,”
BMC Microbiology, vol. 8, article 112, 2008.
[18] A. Agarossi, E. Ferrazzi, F. Parazzini, C. F. Perno, and
L. Ghisoni, “Prevalence and type distribution of high-risk
human papillomavirus infection in women undergoing vol-
untary cervical cancer screening in Italy,” Journal of Medical
Virology, vol. 81, no. 3, pp. 529–535, 2009.
[19] S. K. Kjær, G. Breugelmans, C. Munk, J. Junge, M. Watson,
and T. Iftner, “Population-based prevalence, type- and age-
speciﬁc distribution of HPV in women before introduction
of an HPV-vaccination program in Denmark,” International
Journal of Cancer, vol. 123, no. 8, pp. 1864–1870, 2008.
[20] K. Kov´ acs, A. D. Varnai, M. Bollmann, et al., “Prevalence
and genotype distribution of multiple human papillomavirus
infection in the uterine cervix: a 7.5-year longitudinal study
in a routine cytology-based screening population in West
Germany,” Journal of Medical Virology, vol. 80, no. 10, pp.
1814–1823, 2008.
[21] M. T. Sandri, D. Riggio, M. Salvatici, et al., “Typing of human
papillomavirus in women with cervical lesions: prevalence
and distribution of diﬀerent genotypes,” Journal of Medical
Virology, vol. 81, no. 2, pp. 271–277, 2009.
[22] J.-L. Pr´ etet, A.-C. Jacquard, X. Carcopino, et al., “Human
papillomavirus genotype distribution in high grade cervical
lesions (CIN 2/3) in France: EDITH study,” International
Journal of Cancer, vol. 122, no. 2, pp. 424–427, 2008.